Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

Eli Lilly & Co. (LLY) shares have come under significant pressure in late May following a pivotal decision by CVS Health's ...

Although as of this week the stock has declined by more than 4% since the start of the year, there's little reason to believe ...

The world’s largest pharmaceutical stock, Eli Lilly and Company LLY, recently had its worst day in a long, long time. On May 1, Lilly reported Q1 earnings. Afterwards, shares got beaten down by ...

Shares of Eli Lilly plunged 11% on Thursday. But several Wall Street analysts said the selloff was overblown. "In our view, the Novo/CVS deal does not represent the beginning of an obesity ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to-earnings-to-growth (PEG) ratio of 0.4. PEGs below 1 are generally ...